The Insulin-like Growth Factor-binding Protein 7 (IGFBP-7) ELISA is an enzyme immunoassay for the quantitative determination of Insulin-like Growth Factor-binding Protein 7 (IGFBP-7) in human serum, plasma, and urine.
The microtiter plate is coated with the antibody specifically binding Insulin-like Growth Factor-binding Protein 7. The human serum, plasma or urine is incubated in the plate with the capture antibody. The specimen is washed out and the specifically bound protein is incubated with HRP-labelled detection antibody. Unbound reagent is then washed out. Horseradish peroxidase (HRP) bound in the complex reacts with the chromogenic substrate (TMB) creating the blue color. The reaction is stopped by addition of STOP solution (H2SO4). The absorbance values are measured at 450 nm (optionally 450/630 nm) and are proportional to the concentration of the Insulin-like Growth Factor-binding Protein 7 the specimen. The concentration of Insulin-like Growth Factor-binding Protein 7 in unknown samples is determined from the calibration curve which is created by plotting the absorbance values against the standard concentration values.
Catalog No:BA1024
Regular price
$560.00 USD
Regular price
$560.00 USD
Sale price
$560.00 USD
Unit price/ per
Sale
Sold out
2 weeks
Couldn't load pickup availability
Product Details
Species ReactivityHuman
Sensitivity0.02 ng/mL
Detection Range0.125 - 4 ng/mL
Sample TypeSerum, Plasma, Urine
Sample Size5 uL
Incubation(s)3 hour(s)
Research AreasNephrology
BackgroundIGFBP=7 is a member of the insulin superfamily of growth promoting peptides, and is one of the most abundant and common growth factor polypeptides. IGFBPs are a class of secreted proteins that is able to interact with many ligands other than IGFs.
Currently, IGFBP-7 has been used as an early diagnosis and prognostic marker for acute renal insufficiency (AKI). IGFBP-7, and TIMP-2 concentrations in the urine of children after receiving injections of contrast medium increased faster than SCr. The combination of IGFBP-7 and TIMP-2 was better than either analyte alone (the specificity was 80.0%, and the sensitivity was 81.2%). Two studies suggest the urine compound of TIMP-2 and IGFBP-7 may be used as a biomarker for risk assessment of AKI in ICU patients.
IGFBP-7 has also been proposed as a potential prognostic biomarker in heart failure (HF). It provided prognostic information incremental to clinical variables, NT-proBNP, and hsTnT.
